ABVC Biopharma FY26 Q2 net loss narrows 65% to $810,481 - ABVC News | RalliesABVC Biopharma FY26 Q2 net loss narrows 65% to $810,481
A
ABVC• First-half results and business updates
- For the first half, net loss narrowed 24% to $2.5 million; operating expenses declined 21% to $2.35 million.
- Working capital deficit widened to $5.28 million; BioKey Cayman distribution was postponed, while Vitargus Phase II remains on hold after SAEs.
Second-quarter results and expense trends
- ABVC Biopharma posted a Q2 net loss of $810,481, narrowing 65% from the year-earlier quarter.
- Operating loss tightened to $779,526 as operating expenses fell 66% to $779,526, on lower stock-based compensation.
- Interest expense eased 62% to $41,640, helping offset other expense rising to $30,955 from $14,223.
•
